The Clinical Outcome of FLAG Chemotherapy without Idarubicin in Patients with Relapsed or Refractory Acute Myeloid Leukemia

A refractory and resistant disease to conventional induction chemotherapy and relapsed disease are considered as the most important adverse prognostic factors for acute myeloid leukemia (AML). Sixty-one patients (median age, 33.6 yr) with relapsed or refractory AML were treated with the FLAG regimen...

Descripción completa

Detalles Bibliográficos
Autores principales: Lee, Se Ryeon, Yang, Deok Hwan, Ahn, Jae Sook, Kim, Yeo Kyeoung, Lee, Je Jung, Choi, Young Jin, Shin, Ho Jin, Chung, Joo Seop, Cho, Yoon Young, Chae, Yee Soo, Kim, Jong Gwang, Sohn, Sang Kyun, Kim, Hyeoung Joon
Formato: Texto
Lenguaje:English
Publicado: The Korean Academy of Medical Sciences 2009
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2698199/
https://www.ncbi.nlm.nih.gov/pubmed/19543516
http://dx.doi.org/10.3346/jkms.2009.24.3.498

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2698199/
https://www.ncbi.nlm.nih.gov/pubmed/19543516
http://dx.doi.org/10.3346/jkms.2009.24.3.498

Ejemplares similares